BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11725176)

  • 1. Cyclosporin-induced hypertension.
    Cífková R; Hallen H
    J Hypertens; 2001 Dec; 19(12):2283-5. PubMed ID: 11725176
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation.
    Morales JM; Andres A; Rengel M; Rodicio JL
    Nephrol Dial Transplant; 2001; 16 Suppl 1():121-4. PubMed ID: 11369839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttransplant hypertension.
    Curtis JJ
    Transplant Proc; 1998 Aug; 30(5):2009-11. PubMed ID: 9723370
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms and consequences of arterial hypertension after renal transplantation.
    Koomans HA; Ligtenberg G
    Transplantation; 2001 Sep; 72(6 Suppl):S9-12. PubMed ID: 11585243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is it possible to prevent kidney problems caused by immunosuppression?].
    Aitio ML
    Duodecim; 2000; 116(5):511-9. PubMed ID: 11787104
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
    Friemann S; Feuring E; Padberg W; Ernst W
    Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A?
    Hudnall SD
    Transplantation; 2002 Sep; 74(6):757-8. PubMed ID: 12369583
    [No Abstract]   [Full Text] [Related]  

  • 8. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation.
    Woo M; Przepiorka D; Ippoliti C; Warkentin D; Khouri I; Fritsche H; Körbling M
    Bone Marrow Transplant; 1997 Dec; 20(12):1095-8. PubMed ID: 9466284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.
    Olyaei AJ; de Mattos AM; Bennett WM
    Drug Saf; 1999 Dec; 21(6):471-88. PubMed ID: 10612271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin A-associated hypertension--pathomechanisms and clinical consequences.
    Haas M; Mayer G
    Nephrol Dial Transplant; 1997 Mar; 12(3):395-8. PubMed ID: 9075115
    [No Abstract]   [Full Text] [Related]  

  • 11. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up?
    Groetzner J; Meiser BM; Schirmer J; Koglin J; vScheidt W; Klauss V; Cremer P; Reichenspurner H; Reichart B
    Transplant Proc; 2001; 33(1-2):1461-4. PubMed ID: 11267373
    [No Abstract]   [Full Text] [Related]  

  • 12. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of immunosuppressive regimes on posttransplant diabetes mellitus.
    Weir M
    Transplant Proc; 2001 Aug; 33(5A Suppl):23S-26S. PubMed ID: 11498201
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity.
    Klein IH; Abrahams AC; van Ede T; Oey PL; Ligtenberg G; Blankestijn PJ
    J Hypertens; 2010 Sep; 28(9):1928-34. PubMed ID: 20577127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolic effects of cyclosporin and tacrolimus.
    Marchetti P; Navalesi R
    J Endocrinol Invest; 2000; 23(7):482-90. PubMed ID: 11005276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of tacrolimus (FK506) and cyclosporin A (CyA) on peripheral serotonergic mechanisms in uremic rats.
    Mysliwiec J; Azzadin A; Chabielska E; Takada A; Mysliwiec M; Buczko W
    Thromb Res; 1996 Jul; 83(2):175-81. PubMed ID: 8837316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporin-induced hypertension: incidence, pathogenesis and management.
    Taler SJ; Textor SC; Canzanello VJ; Schwartz L
    Drug Saf; 1999 May; 20(5):437-49. PubMed ID: 10348094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. For organ transplant recipients, cancer threatens long-term survival.
    Ross K
    J Natl Cancer Inst; 2007 Mar; 99(6):421-2. PubMed ID: 17374827
    [No Abstract]   [Full Text] [Related]  

  • 19. Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation--is tacrolimus the answer?
    Grupp C; Schmidt F; Braun F; Lorf T; Ringe B; Müller GA
    Nephrol Dial Transplant; 1998 Jul; 13(7):1629-31. PubMed ID: 9681701
    [No Abstract]   [Full Text] [Related]  

  • 20. Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?
    Schlaich MP; Grassi G
    J Hypertens; 2010 Sep; 28(9):1809-10. PubMed ID: 20699713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.